Athens Renal Center, Llc is a medicare approved dialysis facility center in Athens, Georgia and it has 17 dialysis stations. It is located in Clarke county at 2047 Prince Avenue, Athens, GA, 30606. You can reach out to the office of Athens Renal Center, Llc at (706) 549-2133. This dialysis clinic is managed and/or owned by American Renal Associates. Athens Renal Center, Llc has the following ownership type - Profit. It was first certified by medicare in June, 2014. The medicare id for this facility is 112886 and it accepts patients under medicare ESRD program.
| Name | Athens Renal Center, Llc |
|---|---|
| Location | 2047 Prince Avenue, Athens, Georgia |
| No. of Dialysis Stations | 17 |
| Medicare ID | 112886 |
| Managed By | American Renal Associates |
| Ownership Type | Profit |
| Late Shifts | No |
| 2047 Prince Avenue, Athens, Georgia, 30606 | |
| (706) 549-2133 | |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
| NPI Number | 1912320631 |
| Doing Business As | Athens Renal Center Llc |
| Address | 2047 Prince Ave Athens, Georgia, 30606 |
| Phone Number | (706) 549-2133 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 32 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 72 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 60 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 537 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 12 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 105 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 100 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Athens Renal Center, Llc with elevated calcium levels.
| Patients with hypercalcemia | 80 |
| Hypercalcemia patient months | 760 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 88 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 40 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 15 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 64 |
| Patient months included in arterial venous fistula and catheter summaries | 479 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 45 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 19 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 68 |
| Hospitalization Rate in facility | 172.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 317.9 |
| Hospitalization Rate: Lower Confidence Limit | 96.8 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Athens Renal Center, Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 17.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 29.9 |
| Readmission Rate: Lower Confidence Limit | 9.3 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Athens Renal Center, Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.13 (As Expected) |
| SIR: Upper Confidence Limit | 2.35 |
| SIR: Lower Confidence Limit | .46 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Athens Renal Center, Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 51 |
| Transfusion Rate in facility | 48.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 157.3 |
| Transfusion Rate: Lower Confidence Limit | 17.2 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Athens Renal Center, Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 190 |
| Mortality Rate in facility | 22.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 34.1 |
| Mortality Rate: Lower Confidence Limit | 13.5 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago
Fresenius Medical Care Clarke County Location: 5105 Jefferson Rd Suite B, Athens, Georgia, 30607 Phone: (706) 549-6885 |
Athens East Dialysis Location: 2026 S Milledge Ave, Street A2, Athens, Georgia, 30605 Phone: (706) 549-3297 |
News Archive
About 3,400 California residents whose health insurance was canceled by Kaiser Permanente, Health Net and PacifiCare soon will be notified that they might be eligible for new coverage and compensation for medical bills incurred while they were uninsured, the Los Angeles Times reports.
Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.
Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.
The National Journal notes the two presidential candidates offer clear contrasts when it comes to their positions regarding health insurance. Meanwhile, Roll Call notes that the reported differences in opinions among the Supreme Court justices when they reviewed the health law continue to reverberate during this campaign season.
Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.
› Verified 5 days ago